On June 14, 2022, the Senate HELP (Health, Education, Labor, & Pensions) Committee has passed the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348). The legislation contains provisions establishing mandatory product listing (MPL) requirements for dietary supplements from January 1, 2024 in “Sec. 811. Regulation of dietary supplements“. The measure also grants FDA with a new authority to enforce against products “marketed as” dietary supplements that do not meet the law’s definition of “dietary supplement”.
The proposal for a mandatory product listing (MPL) for dietary supplements in the United States has been subject to a great deal of debate since numerous months, and particularly with the introduction of the Dietary Supplement Listing Act of 2022 from Senators Dick Durbin and Mike Braun in April 2022.
Concretely, this proposal requires those responsible for the marketing of dietary supplement to list their products with FDA from January 1, 2024. If this law is fully validated, it will have a big impact for the companies that market dietary supplements in the United States, they will have to send detailed information for all their dietary supplements to the FDA.